Renalytix (AIM:RENX), the AIM-listed precision medicine diagnostics company focused on kidney disease, has signed a multi-year agreement with Quest Diagnostics to make its kidneyintelX.dkd test available through Quest's network across the United States.
Quest serves roughly half of all physicians and hospitals in the country, giving Renalytix a route to scale distribution of a test currently performed at its New York laboratory.
kidneyintelX.dkd is the only test with FDA authorisation and Medicare reimbursement to predict progressive kidney function decline in patients with type 2 diabetes and early-stage chronic kidney disease, a population Renalytix estimates at 15 million adults in the US.
Under the agreement, physicians will order the test directly through their existing Quest accounts and electronic health records, while patients can use Quest's 2,000 patient service centres and 6,000 in-office phlebotomists for blood draws.
Renalytix will continue to perform and bill for the test itself.
Quest has secured an option to in-license kidneyintelX.dkd once certain commercialisation milestones are reached, a structure that ties the partner's deeper commitment to actual uptake rather than guaranteeing it upfront.
The company points to Medicare spending on chronic kidney disease exceeding $130 billion annually as the cost backdrop the test is designed to address, by flagging risk before patients reach dialysis or transplantation.
kidneyintelX.dkd is expected to be available for physician ordering through Quest's connectivity services in the first quarter of 2027.
News Intelligence what this means for the company
Renalytix has secured distribution through Quest Diagnostics, which serves roughly half of all US physicians and hospitals, giving the company access to 2,000 patient service centres and 6,000 phlebotomists for its kidneyintelX.dkd test. The deal ties Quest's option to in-license the technology to hitting commercial milestones rather than guaranteeing upfront commitment, meaning Renalytix must prove uptake to unlock deeper partnership value—but the distribution infrastructure itself removes a major scaling bottleneck for a test addressing a 15 million-patient addressable market in early-stage kidney disease.
This materially expands Renalytix's route to market from its own New York lab to a national network, but the conditional in-licensing option means Quest's deeper commitment—and the revenue upside it implies—depends on actual physician adoption starting in Q1 2027. The deal does not guarantee volume or revenue; it removes friction to ordering and testing.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
